Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Debt (2023 - 2026)

Perspective Therapeutics' Non-Current Debt history spans 4 years, with the latest figure at $1.6 million for Q1 2026.

  • On a quarterly basis, Non-Current Debt fell 3.54% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 million, a 3.54% decrease, with the full-year FY2025 number at $1.6 million, down 3.45% from a year prior.
  • Non-Current Debt hit $1.6 million in Q1 2026 for Perspective Therapeutics, down from $1.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for CATX hit a ceiling of $1.7 million in Q1 2023 and a floor of $1.6 million in Q1 2026.
  • Historically, Non-Current Debt has averaged $1.6 million across 4 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Non-Current Debt: dropped 2.92% in 2024 and later dropped 3.54% in 2026.
  • Tracing CATX's Non-Current Debt over 4 years: stood at $1.7 million in 2023, then dropped by 3.04% to $1.6 million in 2024, then fell by 3.45% to $1.6 million in 2025, then decreased by 0.96% to $1.6 million in 2026.
  • Business Quant data shows Non-Current Debt for CATX at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.